Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?

The cannabis industry remains a volatile frontier for investors seeking long-term growth. As the market matures, deciding between Canopy Growth (NASDAQ:CGC) and Tilray Brands (NASDAQ:TLRY) requires a careful look at their diverging paths.

Canopy Growth is doubling down on a lean, brand-focused model with a heavy emphasis on its future U.S. presence. Tilray Brands has transformed into a diversified consumer goods giant, leaning on its beverage and wellness segments. Both companies aim to lead the global market, but their strategies and financial health differ significantly.

The case for Canopy Growth

Canopy Growth produces and sells cannabis-based products with a focus on high-quality medical and adult-use segments. In its latest annual report, filed for the period ending March 31, 2026, the company detailed its focus on international markets like Germany and its U.S. expansion strategy through Canopy USA. Canopy Growth maintains supply agreements with all Canadian provinces, and such customer concentration adds a layer of risk to the business.

In FY 2026, revenue reached approximately $203.2 million, representing a growth rate of nearly 5.8% compared to the previous year. Despite this growth, the company reported a net loss of close to $187.7 million for the period, resulting in a negative net margin of roughly 92.4%. The company continues to navigate a challenging landscape among pharmaceutical stocks and cannabis producers.

As of its March 2026 balance sheet, the debt-to-equity ratio is approximately 0.4x, which compares total debt to shareholder equity and suggests a relatively manageable level of leverage. The current ratio, measuring the ability to cover short-term debts with short-term assets, is roughly 3.3x. For the fiscal year, free cash flow was nearly negative $49.8 million, representing cash from operations minus capital expenditures.

The case for Tilray Brands

Tilray Brands operates as a global consumer products company with a diverse portfolio spanning cannabis, wellness, and craft beverages. In its latest annual report, which covers FY 2026, the company highlighted its distribution network including partners like Southern Glazer's for its spirits business. This multi-pronged approach allows the company to reach a broad range of customers beyond traditional cannabis users in more than 20 countries.

In FY 2026, revenue reached approximately $915.5 million, which was an increase of about 11% year over year. The company reported a net loss of $105.2 million for the fiscal year, translating to a net margin of roughly negative 11.5%. Management has focused on diversifying into the craft beer industry to help stabilize its overall top line and reduce dependence on cannabis.

As of its May 2026 balance sheet, Tilray Brands has a debt-to-equity ratio of approximately 0.2x, indicating that its total debt is low relative to its shareholder equity. The current ratio is roughly 2.2x, suggesting the company has enough liquid assets to meet its immediate financial obligations. During FY 2026, free cash flow was approximately negative $98.6 million which is cash flow from operations minus capital expenditures.

Risk profile comparison

Canopy Growth faces several critical risks, including the recent restatement of prior financial statements and the identification of a material weakness in internal controls. The company also deals with significant regulatory uncertainty regarding U.S. federal cannabis laws and ongoing investigations into its BioSteel business. Furthermore, its expansion strategy relies on Canopy USA, where the potential failure of assets like Acreage could materially harm its financial results.

Tilray Brands must manage the complexities of operating in highly regulated markets across multiple continents. The company has grown rapidly through acquisitions like BrewDog and Lyphe Group, which carries the risk of integration challenges or future asset impairments. It also faces competition from licensed producers like TerrAscend (OTC:TSNDF) and deals with various pending class action lawsuits that could lead to significant financial liabilities.

Valuation comparison

Tilray Brands currently offers a lower P/S ratio and a more favorable Forward P/E based on future earnings estimates compared to Canopy Growth.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

The cannabis sector of the stock market can be a risky place to invest, even among the top names in the industry, like Tilray and Canopy Growth. The two largest publicly traded cannabis companies in Canada have taken different approaches, with Tilray pivoting to acquire a massive U.S. craft beverage footprint while Canopy focuses on a more streamlined medical and adult-use marijuana business.

Tilray released fiscal first-quarter earnings results on Oct. 8 that featured revenue growth in its beer and distribution segment but heavy losses in its core cannabis unit. The stock sank on the news, but some risk-tolerant investors may find it to be an attractive entry point. Certainly, Tilray's diversification into craft beverages has helped it offset the higher-risk cannabis trade, especially as U.S. federal legalization remains out of reach. But that also adds business complexity, acquisition cost, and fuel expenses related to distribution on a scale that Canopy, as a more pure play on cannabis, doesn't have to contend with.

Investors who appreciate the wider portfolio may favor Tilray here, while those who are focused on the potential of the cannabis trade may prefer to dig into Canopy's financial prospects. Just be aware of the risks associated with investing in this market segment and allocate your positions appropriately.

Sarah Sidlow has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy.